Chapter 2. Oncogenes, Translocations, and Surface Antigens: Keys to Diagnosis and Rational Therapy
2.1. Chromosomal Alterations as Defining Signs
2.2. Computer-Assisted Cytogenetic Diagnostics: Invaluable Aids for Therapy Selection
2.3. Lymphocyte Surface Antigens as Diagnostic Markers and Therapy Targets
2.4. A Limited Role for In Vivo Imaging
2.5. Molecular Biology for Diagnosis and Monitoring of Hematological Malignancies

Chapter 3. Current Therapies and Unmet Need
3.1. Small Molecules
Steroids
Alkylating Agents
Mitotic Spindle Modulators
Antimetabolites
DNA Hypomethylating Agents and Histone Deacetylase Inhibitors
3.2. Proteins and Antibodies
Enzymes
Monoclonal Antibodies
3.3. Acute Lymphocytic Leukemia
3.4. Chronic Lymphocytic Leukemia
3.5. Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
3.6. Myelodysplastic Syndromes
3.7. Chronic Myeloid Leukemia
3.8. Hodgkin’s Disease
3.9. Non–Hodgkin’s Lymphoma
Rituxan
The Bexxar Regimen
Zevalin
3.10. Myeloma and Plasmacytoma

Chapter 4. Newly-Approved Drugs and Candidates in Development
4.1. New Formulations
Marqibo: A Liposomal Vincristine
A New Formulation of Aminopterin
Ceplene plus Interleukin-2
4.2. Nucleotide Analog Antimetabolites
Clofarabine
Next in Line: Dacogen
Arranon (Nelarabine)
4.3. New Alkylating Agents
Cloretazine
Treanda (Bendamustine)
4.4. Protein Kinase Inhibitors
BMS-354825 and AMN-107: Overcoming Gleevec Resistance?
Sorafenib
Lestaurtinib
Tandutinib
VX-680
4.5. Topoisomerase Inhibitors
Pixantrone
Banoxantrone
Annamycin
Elsamitrucin: A Natural Compound
4.6. Histone Deacetylase Inhibitors
PXD-101
Merck’s SAHA (Suberanilohydroxamic Acid)
4.7. New Mechanisms, New Uses
Fodosine: A New Hope for T-Cell Malignancies
Farnesyltransferase Inhibitors
-Zarnestra
-Sarasar
ABT-510
Telik’s Telintra
An Emerging Strategy: Heat Shock Protein Inhibitors
Noscapine
Aplidine
Potential Use Extensions for Proleukin
Two Broader Uses for Trisenox
Velcade in Mantle Cell Lymphoma
SDX-101: A New Application for an Old Nonsteroidal Anti-Inflammatory Drug
Pharmacyclics’ Xcytrin: Second Uses in Blood Malignancies
4.8. Small-Molecule Immune Modulators
Celgene Corporation’s Revlimid: A Thalidomide Analog for Myelodysplastic Syndromes
Ziopharm’s Follow-Up Candidates on Trisenox
Talabostat
4.9. Antisense Drugs
Genasense
MG-98
LR3001: A New c-myb Antisense Drug
GTI-2040
SPC-2996
4.10. Vaccines, Cell Therapies, and Protein Immunostimulators
Stimulated Autologous T Cells
Gene Therapy with Transduced Autologous Cells
GVAX: An Adoptive Immunotherapy
An Anti-Idiotype Vaccine for Non–Hodgkin’s Lymphoma
PR1 Antigen Elicits Cellular Immune Response against Myeloid Leukemia Cells
LymphoRad: A Radiolabeled B-Cell Stimulator
4.11. Monoclonal Antibodies
The HuMax Series
Lintuzumab
AVE-9633
An Antibody-Targeted Immunotoxin

Chapter 5. Structure of the Hematological Cancer Market and Its Perspectives

Chapter 6. Company Profiles
6.1. Actinium Pharmaceuticals, Inc.
6.2. BioCryst Pharmaceuticals, Inc.
6.3. Celgene Corporation
6.4. Cell Genesys, Inc.
6.5. Cell Therapeutics, Inc.
6.6. Genencor International, Inc.
6.7. Inex Pharmaceuticals Corporation
6.8. Lorus Therapeutics, Inc.
6.9. Pharmion Corporation
6.10. Vion Pharmaceuticals, Inc.

References

Glossary

Index